Cantor Fitzgerald Begins Coverage on Aquestive Therapeutics

Cantor Fitzgerald has officially started its coverage of Aquestive Therapeutics (NASDAQ:AQST) as of Tuesday. According to their report, they have assigned an "overweight" rating to the stock, along with a price target of $17.00. This price target suggests a significant potential upside of 372.22% based on the company's prior closing price.

Recently, other research analysts have also provided their insights on Aquestive Therapeutics' stock. Leerink Partners raised their price target from $12.00 to $13.00, giving the company an "outperform" rating in a report dated October 25th. Meanwhile, HC Wainwright maintained a "buy" rating alongside a price target of $10.00 in a report released on November 6th. Additionally, JMP Securities has confirmed a "market outperform" rating with a price target of $9.00 as of October 8th. In total, six analysts have rated the stock as a buy, while one has issued a strong buy rating. Current consensus data reveals that Aquestive Therapeutics has an overall rating of "Buy" with a target price averaging around $11.00.

Aquestive Therapeutics Stock Performance

On Tuesday, the stock opened at $3.60. In the last twelve months, Aquestive Therapeutics has reached a low of $1.84 and a high of $6.23. The company's shares have a 50-day moving average of $4.83 and a 200-day average of $4.06. Currently, Aquestive Therapeutics boasts a market capitalization of approximately $328.24 million, along with a price-to-earnings ratio of -8.00 and a beta value of 2.62.

In its most recent quarterly earnings report released on November 4th, Aquestive Therapeutics reported earnings of ($0.13) per share, which fell short of analysts' expectations that predicted ($0.12) per share. The company generated revenues amounting to $13.54 million during the quarter, surpassing the projected $12.69 million. In the same quarter last year, the company had reported earnings of ($0.03) per share. Analysts forecast that for the current fiscal year, Aquestive Therapeutics will post an earnings per share (EPS) of -0.47.

Institutional Investments in Aquestive Therapeutics

Several institutional investors and hedge funds have recently adjusted their positions in Aquestive Therapeutics. State Street Corp has notably increased its stake by 52.1% during the third quarter, now holding 1,496,739 shares worth about $7.45 million after acquiring an additional 512,682 shares. Blue Owl Capital Holdings LP also boosted its holdings by 30.3% during the second quarter, now owning 1,140,000 shares valued at $2.96 million after adding 265,000 shares. The Bank of New York Mellon Corp initiated a new position during the second quarter for approximately $594,000. Furthermore, Verition Fund Management LLC purchased a new stake during the third quarter valued at around $995,000, and Wellington Management Group LLP added a position during the same period worth about $922,000. Presently, institutional investors collectively own about 32.45% of the company's stock.

Overview of Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company both in the U.S. and internationally. The firm markets various products including Sympazan, an oral soluble film formulation of clobazam designed for treating Lennox-Gastaut syndrome, and Suboxone, a sublingual film formulation of buprenorphine and naloxone meant for addressing opioid dependence. Other key products include Zuplenz, an oral film for treating nausea and vomiting related to chemotherapy and recovery from surgery, and Azstarys, a daily treatment option for attention deficit hyperactivity disorder.

stocks, analysis, investment